Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 78, Issue 1, 2007, Pages 93-95

  Daousi, C ^a   Foy, P M ^b   MacFarlane, I A ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; GADOLINIUM; PROTIRELIN; RADIOACTIVE IODINE; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; EUTHYROIDISM; FEMALE; FOLLOW UP; HUMAN; HYPERTHYROIDISM; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; THYROIDECTOMY; THYROTOXICOSIS; THYROTROPIN SECRETING ADENOMA; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME;

EID: 33845990243     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2006.095661     Document Type: Article

References (15)

1. Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996;17:610-38.
2. Patrick AW, Atkin SL, MacKenzie J, et al. Hyperthyroidism secondary to a pituitary adenoma secreting TSH, FSH, alpha-subunit and GH. Clin Endocrinol (Oxford) 1994;40:275-8.
3. Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 1993;119:236-40.
4. Gancel A, Vuillermet P, Legrand A, et al. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol (Oxford) 1994;40:421-8.
5. Comi RJ, Gesundheit N, Murray L, et al. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med 1987;317:12-17.
6. Kuhn JM, Arlot S, Lefebvre H, et al. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 2000;85:1487-91.
7. Caron P, Arlot S, Bauters C, et al. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 2001;86:2849-53.
8. Taylor TJ, Donlon SS, Bale AE, et al. Treatment of a thyrotropinoma with octreotide-LAR in a patient with multiple endocrine neoplasia-1. Thyroid 2000;10:1001-7.
9. Beck-Peccoz P, Mariotti S, Guillausseau PJ, et al. Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995. J Clin Endocrinol Metab 1989;68:208-14.
10. Brucker-Davis F, Oldfield EH, Skarulis MC, et al. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 1999;84:476-86.
11. Filetti S, Rapoport B, Aron DC, et al. TSH and TSH-subunit production by human thyrotrophic tumour cells in monolayer culture. Acta Endocrinol (Copenh) 1982;99:224-31.
12. Jaquet P, Hassoun J, Delori P, et al. A human pituitary adenoma secreting thyrotropin and prolactin: immunohistochemical, biochemical, and cell culture studies. J Clin Endocrinol Metab 1984;59:817-24.
13. Lamberts SW, Oosterom R, Verleun T, et al. Regulation of hormone release by cultured cells from a thyrotropin-growth hormone-secreting pituitary tumor. Direct inhibiting effects of 3,5,3′-triiodothyronine and dexamethasone on thyrotropin secretion. J Endocrinol Invest 1984;7:313-17.
14. Le DM, Brandi AM, Kujas M, et al. Thyrotropin-releasing hormone (TRH) binding sites and thyrotropin response to TRH are regulated by thyroid hormones in human thyrotropic adenomas. Eur J Endocrinol 1994;130:559-64.
15. Sarapura VD, Wood WM, Gordon DF, et al. Effect of thyroid hormone on T3-receptor mRNA levels and growth of thyrotropic tumors. Mol Cell Endocrinol 1993;91:75-81.